J 2022

Extended Mechanism of the Plasminogen Activator Staphylokinase Revealed by Global Kinetic Analysis: 1000-fold Higher Catalytic Activity than That of Clinically Used Alteplase

TOUL, Martin, Dmitri NIKITIN, Martin MAREK, Jiří DAMBORSKÝ, Zbyněk PROKOP et. al.

Basic information

Original name

Extended Mechanism of the Plasminogen Activator Staphylokinase Revealed by Global Kinetic Analysis: 1000-fold Higher Catalytic Activity than That of Clinically Used Alteplase

Authors

TOUL, Martin (203 Czech Republic, belonging to the institution), Dmitri NIKITIN (643 Russian Federation, belonging to the institution), Martin MAREK (203 Czech Republic, belonging to the institution), Jiří DAMBORSKÝ (203 Czech Republic, guarantor, belonging to the institution) and Zbyněk PROKOP (203 Czech Republic, belonging to the institution)

Edition

ACS Catalysis, WASHINGTON, AMER CHEMICAL SOC, 2022, 2155-5435

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10403 Physical chemistry

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 12.900

RIV identification code

RIV/00216224:14310/22:00126168

Organization unit

Faculty of Science

UT WoS

000784255800008

Keywords in English

staphylokinase; plasminogen activator; kinetic mechanism; global numerical analysis; rate-limiting step; catalytic activity; thrombolytic; fibrin

Tags

Tags

International impact, Reviewed
Změněno: 3/4/2023 09:28, Mgr. Marie Šípková, DiS.

Abstract

V originále

The plasminogen activator staphylokinase is a fibrin-specific thrombolytic biomolecule and an attractive target for the development of effective myocardial infarction and stroke therapy. To engineer the protein rationally, a detailed understanding of the biochemical mechanism and limiting steps is essential. Conventional fitting to equations derived on the basis of simplifying approximations may be inaccurate for complex mechanisms such as that of staphylokinase. We employed a modern numerical approach of global kinetic data analysis whereby steady-state kinetics and binding affinity data sets were analyzed in parallel. Our approach provided an extended, revised understanding of the staphylokinase mechanism without simplifying approximations and determined the value of turnover number k(cat) of 117 s(-1) that was 10000-fold higher than that reported in the literature. The model further showed that the rate-limiting step of the catalytic cycle is binding of staphylokinase to plasmin molecules, which occurs via an induced-fit mechanism. The overall staphylokinase effectivity is further influenced by the formation of an inactive staphylokinase.plasminogen complex. Here, we describe a quick and simplified guide for obtaining reliable estimates of key parameters whose determination is critical to fully understand the staphylokinase catalytic functionality and define rational strategies for its engineering. Our study provides an interesting example of how a global numerical analysis of kinetic data can be used to better understand the mechanism and limiting factors of complex biochemical processes. The high catalytic activity of staphylokinase (more than 1000-fold higher than that of the clinically used drug alteplase) determined herein makes this thrombolytic agent a very attractive target for further engineering.

Links

EF17_043/0009632, research and development project
Name: CETOCOEN Excellence
EF19_073/0016943, research and development project
Name: Interní grantová agentura Masarykovy univerzity
LM2018121, research and development project
Name: Výzkumná infrastruktura RECETOX (Acronym: RECETOX RI)
Investor: Ministry of Education, Youth and Sports of the CR, RECETOX RI
LM2018127, research and development project
Name: Česká infrastruktura pro integrativní strukturní biologii (Acronym: CIISB)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/H/1561/2018, interní kód MU
Name: Decoding the molecular principles of enzyme evolution
Investor: Masaryk University, Individual High risk/high gain projects
TN01000013, research and development project
Name: Personalizovaná medicína - diagnostika a terapie
Investor: Technology Agency of the Czech Republic, Personalized Medicine – Diagnostics and Therapy
857560, interní kód MU
(CEP code: EF17_043/0009632)
Name: CETOCOEN Excellence (Acronym: CETOCOEN Excellence)
Investor: European Union, Spreading excellence and widening participation